Trial · NCT05987176
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
NCT05987176, Phase 2, Terminated, Imperial College London
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases. Trials, record NCT05987176. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05987176
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
- NCT number
- NCT05987176
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Imperial College London
- Conditions
Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors, Liver Metastases, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm
- Interventions
- Lutathera
- First posted
- 2023-08-14
- Last updated
- 2026-01-14
- Other registries' IDs
- eudract:2022-003575-42
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease free survival | 3 years | To compare overall Disease-Free Survival (DFS) at 3 years after treatment with 177Lu-DOTATATE to best supportive care in patients with R0/R1 resected liver metastases of well differentiated (grade 1 or 2) GEP NET and no extrahepatic disease manifestation prior to randomization in the study. |
| Secondary | Comparison of Disease free survival in the liver between arm | 3 years | To compare the Disease-Free Survival (DFS) in the liver between the two study arms |
| Secondary | Overall survival | 5 years | To compare the overall survival (OS) in the liver between the two study arms |
| Secondary | Time to tumour recurrence | 5 years | To compare the Time to Tumour Recurrence (TTR) between the two study arms |
| Secondary | Comparison Time to next antineoplastic therapy | 5 years | To compare the time to administration of subsequent antineoplastic therapy between the two arms |
| Secondary | Safety and tolerability of 177Lu-DOTATATE (AEs/SAEs/SUSARs) | 5 years | To evaluate the safety and tolerability of 177Lu-DOTATATE |
| Secondary | Evaluation of quality of life | 3 years | To evaluate the health-related Quality of Life (QoL) as measured by the EORTC QLQ-C30, QLQ-GI NET 2.1 and EQ-5D questionnaires |
| Secondary | Evaluation of self reported health perceptions | 3 years | To evaluate patient reported outcomes (PROs) as measured by the Short Form-36® (SF-36) Health Survey |
| Secondary | Cost-effectiveness evaluation | 5 years | To evaluate the cost effectiveness assessed by EuroQol-5D (cost for subsequent therapy) |
| Other | NETest | 3 years | • To explore the clinical utility of novel biomarkers (NETest, PPQ, metabolic signature) in identification of residual microscopic disease and early detection of recurrent disease |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05987176
GET https://conductscience.org/api/trials/v1/NCT05987176/registered